CLINICAL GENOMICS · MASTER COURSE · v1.0

The genome,
read with care.

From sequencing chemistry and ACMG variant calling to methylation clocks, polygenic prediction, and the CRISPR drugs already on pharmacy shelves — taught with claim-grading, ancestry-aware caveats, and three tracks for every clinician.

Start the curriculum Browse the Evidence Grader
12
Modules
3
Tracks
50+
Graded claims
// Three tracks, one course

Choose your depth

Switch tracks anytime in the sidebar. Lessons reveal a foundations explainer, a clinician deep-dive, and an advanced research note depending on your selection.

Track
Foundations

Genome architecture, sequencing technology, and the variant-interpretation framework — for any clinician encountering genomic data.

Track
Clinical

Diagnostic ordering, ACMG variant classification, pharmacogenomics, cancer genomics, and counseling — for prescribers and genetic counselors.

Track
Research

Polygenic prediction, methylation clocks, CRISPR/base/prime editing, in-vivo delivery, and the regulatory frontier — for translational researchers and specialists.

// Curriculum preview · Foundations track

9 modules unlocked

See full curriculum
01
The Human Genome at Scale
3.1 Gb, 20k coding genes, and ~98% of the action outside them.
02
Reading the Genome: Platforms & Modalities
Short-read, long-read, optical mapping, single-cell, methylation — what each modality actually sees.
03
Variant Interpretation: ACMG, VUS, and Penetrance
From a VCF line to a clinical recommendation — the ACMG/AMP framework and where it breaks.
04
Pharmacogenomics in Practice
CYP2C19, TPMT, DPYD, HLA — when a genotype actually changes prescribing.
05
Cancer Genomics: Germline, Somatic, and Liquid
Tumor mutation profiles, MRD by ctDNA, and the germline cases that change family screening.
07
The Epigenome and Methylation Clocks
DNA methylation as the most measurable layer of biological aging — and what it doesn't tell you.

This isn't another "23andMe explained" deck.

The audience is clinicians and translational researchers working with real reports. Casgevy ships at $2.2 M, ctDNA MRD changes adjuvant decisions in colorectal cancer, methylation episignatures resolve previously undiagnosable intellectual disability, base editors are in pivotal cardiovascular trials. We teach the substrate, the evidence grade, and the things being oversold — including by the field's own enthusiasts.